Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs

Jérôme Fortin; Tak W Mak

doi:10.1016/j.ccell.2016.03.020

Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs

Cancer Cell. 2016 Apr 11;29(4):429-431. doi: 10.1016/j.ccell.2016.03.020.

Authors

Jérôme Fortin¹, Tak W Mak²

Affiliations

¹ The Campbell Family Institute for Breast Cancer Research, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada.
² The Campbell Family Institute for Breast Cancer Research, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada; Department of Medical Biophysics, University of Toronto, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada; Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON M5G 2C1, Canada. Electronic address: tmak@uhnresearch.ca.

PMID: 27070694
DOI: 10.1016/j.ccell.2016.03.020

Abstract

AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the unexpected finding that ablation of AKT signaling in hepatocytes leads to hepatocellular carcinoma and enhances the incidence of lung metastases in a toxin-induced liver cancer model.

Publication types

Comment

MeSH terms

Humans
Liver Neoplasms
Lung Neoplasms
Phosphatidylinositol 3-Kinases / metabolism*
Proto-Oncogene Proteins c-akt / metabolism*
Signal Transduction

Substances

Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt